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Our prior studies demonstrated that cellular response of T helper 1 (Th1) type was
generated by a soluble antigenic fraction (ranging from 89.9 to 97.1 kDa) of Leishmania
donovani promastigote, in treated Leishmania patients as well as hamsters and
showed significant prophylactic potential against experimental visceral leishmaniasis
(VL). Eighteen Th1 stimulatory proteins were identified through proteomic analysis of
this subfraction, out of which 15 were developed as recombinant proteins. In the
present work, we have evaluated these 15 recombinant proteins simultaneously for
their comparative cellular responses in treated Leishmania patients and hamsters.
Six proteins viz. elongation factor-2, enolase, aldolase, triose phosphate isomerase,
protein disulfide isomerase, and p45 emerged as most immunogenic as they produced
a significant lymphoproliferative response, nitric oxide generation and Th1 cytokine
response in PBMCs and lymphocytes of treated Leishmania patients and hamsters
respectively. The results suggested that these proteins may be exploited for developing
a successful poly-protein and/or poly-epitope vaccine against VL.
Keywords: Leishmania donovani, recombinant Th1 stimulatory proteins, immunogenicity, cellular response,
lymphocytes, PBMCs, treated Leishmania-infected hamster, treated Leishmania patients
INTRODUCTION
Visceral leishmaniasis (VL), a life-threatening systemic disease also referred as black sickness or
kala-azar, is caused by Leishmania (L.) donovani and L. infantum (chagasi) and is transmitted
to the human host via the bite of infected female dipteran vector, sandfly. This disease is
widespread in the Indian subcontinent, East Africa, Mediterranean basin, Central and South
America. About 90% of the annual 100 000 cases of VL are from India, Sudan, Brazil,
Ethiopia, Bangladesh, and Nepal. Human migration and environmental changes lead to further
expansion of the geographical range of this disease which ultimately affects the epidemiological
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triad (Desjeux, 2004). In India, Bihar serves as the major epicenter
of this disease as it covers 80% of VL cases (Hasker et al.,
2012). Available chemotherapeutics proved to be inadequate
to curb this disease due to its toxicity and are also not cost
effective (Coler et al., 2015). Current kala-azar control roadmap
in the Indian subcontinent is threatened by the occurrence of
relapse cases (Croft et al., 2006; Srivastava et al., 2011; Garcia-
Hernandez et al., 2012; Mohapatra, 2014). Immune response,
in particular, cell-mediated immune (CMI) response, is severely
compromised during active VL, therefore, its up-regulation is
indispensable for the parasite’s clearance (Stanley and Engwerda,
2007). A suitable vaccine against VL offers a viable alternative
keeping in view the fact that Leishmania-infected individuals
generate life-long immunity. Also, considering the existence
of 80–90% of subclinical or asymptomatic Leishmania cases
(endemic healthy contacts) as well as post kala-azar dermal
leishmanoid (PKDL) cases, a safe and effective vaccine will be
critical if the success of recent VL control efforts in Indian
subcontinent is to be sustained (Engwerda and Matlashewski,
2015).
For the reduction of parasitic burden in infected individuals,
generation of interleukin (IL)-2, interferon (IFN)-γ and tumor
necrosis factor (TNF)-α, indicative of T helper 1 (Th1) type
response is essential. Also, there requires a balance between
proinflammatory IFN-γ/TNF-α and regulatory IL-10 cytokines
(Coler et al., 2015). Leishmanial antigens with predominant Th1
type response in infected rodent models have been recognized as
‘potential protective antigens’ and, therefore, promising vaccine
candidates. Based on this, several antigens were evaluated which
shows mild to moderate protection in different animal models
(mice and hamster) and human subjects as reviewed by Joshi et al.
(2014). Moreover, current strategies for vaccine development
have advanced toward immunologically vital miniature antigenic
regions, i.e., the epitopes identified from potential native or
recombinant proteins as they are competent enough to generate
protective immunity against infectious organisms. Furthermore,
designing of vaccines containing multiple epitopes derived from
different antigens, i.e., poly-epitope vaccines fortify the immune
response via targeting multiple antigenic regions. Also, due to
the genetic polymorphism of the mammalian immune system,
a multi-component vaccine thought to elicit a better protective
immune response (Goto et al., 2011).
Our earlier studies, using classical activity based fractionation
and sub-fractionation of the soluble proteins from an Indian
L. donovani promastigote, led to the identification of a
potential sub-fraction (89.9–97.1 kDa) which induced Th1
type cellular response in peripheral blood mononuclear cells
(PBMCs)/lymphocytes of treated Leishmania patients and
hamsters. Furthermore, this fraction also offered significant
prophylactic efficacy in hamsters against Leishmania challenge
(Garg et al., 2006; Kumari et al., 2008a,b). Subsequently, 18
Th1 stimulatory proteins were identified through proteomic
characterization of this subfraction (Kumari et al., 2008b). Of
these, 15 could be developed as recombinant proteins, some
of which were subjected to biochemical and immunological
characterization and were assessed for their suitability as
prophylactic vaccine in hamster model (Kushawaha et al., 2011,
2012a,b; Gupta et al., 2012, 2014; Jaiswal et al., 2014; Khare et al.,
2014; Baharia et al., 2015). In the present communication, all
the recombinant proteins were evaluated simultaneously for their
comparative immunogenicity (cellular responses) in PBMCs and
lymphocytes of treated Leishmania patients as well as hamsters in
order to identify the most potent ones which can be further taken
up for developing potential poly-protein and/or poly-epitope
vaccine against VL.
MATERIALS AND METHODS
Host and Parasite
Golden hamsters (Mesocricetus auratus, 50–55 g) housed
in the climatically controlled room, served as a suitable
experimental host. The care and use of hamsters were monitored
by institutional animal ethics committee (IAEC) which also
approved animal experimentation protocols (Approval No.
150/09/Para/IAEC dated 23.10.09) following guidelines of
committee for the purpose of control and supervision of
experiments on animals (CPCSEA). L. donovani strain
(MHOM/IN/80/Dd8) was procured as promastigotes from
American type culture collection (ATCC, Manassas, VA, USA)
and was maintained in vitro following the protocol of Garg et al.
(2005). Parasite’s virulence was maintained by serial passaging of
amastigote in hamsters (Dube et al., 2005).
Soluble L. donovani (SLD) Promastigote
Antigen and Recombinant Proteins
The preparation of SLD antigen from metacyclic promastigotes
was done as per the method of Gupta et al. (2007) and stored
at −80◦C till further use. Fifteen recombinant Th1 stimulatory
proteins utilized in this study namely elongation factor-2 (elF-2),
p45, aldolase (Aldo), enolase (Eno), triosephosphate isomerase
(TPI), protein disulfide isomerase (PDI), cofactor-independent
phosphoglycerate mutase (iPGM), adenosyl homocysteinase
(ADHT), calreticulin (Cal), heat shock proteins (Hsp) – Hsp70
and Hsp83, trypanothione reductase (TPR), NAD-dependent
deacetylase SIR2 homolog (NAD) and two hypothetical proteins
(Hypo 1 and 2) have been successfully cloned, expressed and
purified. Sequences of all the 15 proteins have been submitted
to the national center for biotechnology information (NCBI) as
depicted in Table 1.
Isolation of Lymph Node Cells from
Treated Leishmania-Infected Hamsters
A total of 40 hamsters were utilized in this study. A 0.1 ml
of inoculum containing 107 amastigotes/ml was injected
intracardially in 30 hamsters while rest of the 10 animals
were kept as uninfected control. The magnitude of infection in
infected animals were assessed 1 month later by performing a
splenic biopsy. Miltefosine (Synphabase, Switzerland), an oral
antileishmanial drug, was administered in 15 out of 30 infected
hamsters @ 40 mg/kg bodyweight daily for 5 days. Remaining 15
animals were kept as infected control. The method of Garg et al.
(2005) was used for isolation of mononuclear lymph node cells.
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TABLE 1 | List of recombinant proteins with their accession no. submitted to the national center for biotechnology information (NCBI).
S. no. Th1 stimulatory proteins Accession no. Approximately weight (in kDa) Nucleotide BLAST
L. major L. infantum
1 Calreticulin EU723848 38 95 99
2 Protein disulfide isomerase EU723849 55 94 99
3 Enolase EU723850 50 97 99
4 p45 EU723851 45 97 99
5 Triose phosphate isomerase EU867389 28 97 99
6 Elongation factor-2 EU929069 70 99 99
7 Aldolase GQ 220750 46 94 97
8 Trypanothione reductase JN007485 55 79 79
9 Adenosyl homocysteinase GU353334 52 88 88
10 Cofactor-independent phosphoglycerate mutase HM044147 67 94 94
11 NAD-dependent deacetylase SIR2 homolog JN790591 45 95 98
12 Heat shock protein 70 HQ011382 60 97 98
13 Heat shock protein 83 HQ230577 83 90 90
14 Hypothetical protein 1 JF957190 55 88 90
15 Hypothetical protein 2 JX855827 150 92 99
Isolation of PBMCs from Treated VL
Patients
Human ethics committee of the kala-azar medical research
center (KMRC), Muzaffarpur approved the protocols and study
on human subjects belonging to hyper-endemic areas of Bihar
(Approval No EC-KAMRC/Vaccine/VL/2007-01). A written
informed consent was also taken from all of them before their
enrollment to this study. All the study subjects, as shown
in Table 2, were examined for leishmanial as well as other
possible infections by a local clinician. Venous blood samples
were collected from one to 6-months-old follow up ambisome
or amphotericin B treated VL patients (confirmed by physical
examination and clinical symptoms) as well as from healthy
contacts (neither showed any clinical symptoms nor received any
treatment for kala-azar). PBMCs were isolated from the collected
venous blood following the method of Garg et al. (2005).
Lymphocyte Proliferation and Nitric
Oxide Assay
A 0.1 ml of cell suspension (PBMCs from treated patients/healthy
contacts and mononuclear cells from treated/uninfected
hamsters) in complete RPMI-1640 (Sigma-Aldrich, USA)
containing 1×106 cells/ml was seeded in 96-well flat-
bottom tissue culture plates (Nunc, Denmark). Each of the
15 recombinant proteins viz. rLdPDI, rLdTPI, rLdelF-2, rLdp45,
rLdAldo, rLdEno, rLdiPGM, rLdADHT, rLdCal, rLdHsp70,
rLdHsp83, rLdTPR, rLdNAD and the two hypothetical proteins-
rLdHypo1 and rLdHypo2 as well as SLD (10 µg/ml/well)
were used separately in triplicate. Phytohemagglutinin (PHA,
10 µg/ml, Sigma-Aldrich, USA) for Patient’s PBMCs and
concanavalin A (ConA, 10 µg/ml, Sigma-Aldrich, USA) for
hamster’s mononuclear cells were used as standard mitogens.
Wells without stimulants served as blank controls. Cells were
maintained in a CO2 incubator (37◦C with 5% CO2) for 3 days
in case of mitogens and for 5 days in case of recombinant
TABLE 2 | Clinical data of treated VL patients and healthy contacts.
S. no. Gender Age Study group Duration of treatment
(approximately in months)
1 Female 45 Healthy contact –
2 Male 50 Healthy contact –
3 Female 42 Healthy contact –
4 Male 22 Healthy contact –
5 Female 35 Healthy contact –
6 Male 45 Healthy contact –
7 Female 45 Healthy contact –
8 Female 28 Healthy contact –
9 Male 35 Healthy contact –
10 Female 20 Cured 6
11 Female 15 Cured 6
12 Female 14 Cured 6
13 Male 15 Cured 6
14 Male 50 Cured 6
15 Male 35 Cured 2
16 Female 20 Cured 3
17 Female 12 Cured 1
18 Female 15 Cured 3
19 Female 40 Cured 1.5
20 Female 30 Cured 1
21 Male 14 Cured 2
22 Male 12 Cured 3.5
proteins. 50 µl of XTT (Biological Industries, Israel) was added
to 100 µl of culture supernatant around 18 h prior to termination
of the experiment. The absorbance of the samples, at 480 nm
with 650 nm as a reference wavelength, was measured in a
SPECTRAmax PLUS 384 microplate reader (Molecular Devices,
USA).
Similarly, nitric oxide (NO) generation was estimated by
co-culturing J774A.1 macrophages with 100 µl supernatant of
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stimulated mononuclear cells for 24 h and then by adding an
equal amount of Griess reagent (Sigma-Aldrich, USA; Garg et al.,
2005). The absorbance of the reaction was measured at 540 nm
(Ding et al., 1988). Lipopolysaccharide (LPS, 10 µg/ml, Sigma-
Aldrich, USA) was used as standard NO producer.
Estimation of Th1/Th2 Cytokines in
Culture Supernatant of PBMCs of
Treated Patients/Healthy Contacts
Peripheral blood mononuclear cells (1 × 106 cells/ml) from
treated human patients as well as healthy contacts were plated in
96-well culture plates (Nunc, Denmark). Recombinant proteins
at a concentration of 10 µg/ml were added to triplicate wells
and incubated for 5 days. The levels of IFN-γ, IL-12, TNF-α,
IL-10, IL-4, and TGF-β (in pg/ml) were estimated in the culture
supernatant by ELISA (enzyme-linked immunosorbent assay) kit
(BD OptEIA, Pharmingen).
Statistical Analysis
Two sets of independent experiments (each containing 3–5
animals) were performed. One-way ANOVA was applied in
cell-proliferation assay and NO estimation by comparing
recombinant proteins group with SLD in treated hamsters as
well as in human patients using GraphPad Prism 6.01 (GraphPad
Software, San Diego, CA, USA). Results were expressed as
mean ± SE. Significance was considered when the p-values
were<0.05.
RESULTS
Recombinant Th1 Stimulatory Proteins
Induce Strong Lymphoproliferative
Response in Treated Leishmania
Hamsters and NO Production in J774
Macrophages
The cellular response generated by lymphocytes isolated
from lymph nodes of treated hamsters as assessed by XTT
against SLD and 15 recombinant proteins have been shown
in Figure 1A. Significantly, a higher proliferative response
against Con A was observed in treated hamsters indicating
the procedural sensitivity (data not shown). Ten recombinant
proteins viz. rLdEno, rLdPDI, rLdTPI, rLdelF-2, rLdp45,
rLdAldo, rLdADHT, rHsp83 and the two hypothetical
proteins- rLdHypo1 and rLdHypo2 showed significantly
higher stimulation in lymphocytes isolated from treated
hamsters (mean OD ± SE 3.510 ± 0.04988, 3.468 ± 0.02080,
3.420 ± 0.05009, 3.650 ± 0.04775, 3.415 ± 0.03242, 3.458 ±
0.05535, 3.303 ± 0.1672, 3.272 ± 0.06071, 3.418 ± 0.03132, and
3.343± 0.1215) than SLD (mean OD± SE 2.346± 0.2640). Rest
of the proteins has shown lesser proliferative response than SLD
which was not statistically significant.
Nitric oxide generation by J774 A.1 was studied since it is
known that NO-mediated macrophage effector mechanism is
critical for reducing parasitic burden in the animal model. NO
production was recorded after 24 h of incubation and was found
to be significantly higher against six recombinant proteins viz.
rLdPDI, rLdTPI, rLdelF-2, rLdp45, rLdAldo, and rLdEno in
comparison to SLD as shown in Figure 1B. NO generation by
LPS stimulated cells served as positive control while unstimulated
cells are considered as a negative control (data not shown).
Recombinant Th1 Stimulatory Proteins
Stimulate Significant
Lymphoproliferative and Predominant
Thl Cytokine Response in Treated VL
Patients
Peripheral blood mononuclear cells of treated Leishmania
patients were further utilized to validate the cellular responses
observed in treated hamsters. There were marked differences
in responses generated by individual donors in each study
group. Figure 2 depicted the lymphocyte proliferation response
generated by 15 recombinant proteins in comparison to SLD.
Seven out of 15 proteins, i.e., rLdPDI, rLdTPI, rLdelF-2, rLdp45,
rLdAldo, rLdEno, and rLdHsp70 showed significantly higher
lymphoproliferative response (3.001± 0.08074, 3.179± 0.04249,
3.164 ± 0.02774, 3.158 ± 0.06383, 3.038 ± 0.03051,
3.098 ± 0.08782, and 3.044 ± 0.01308) in PBMCs from
treated VL patients. The higher proliferative response against
PHA indicated procedural sensitivity (data not shown).
Cytokine responses of those recombinant proteins, that have
shown optimal lymphoproliferative response and NO generation
in both human PBMCs and hamster’s lymphocytes, i.e., rLdEno,
rLdAld, rLdp45, rLdTPI, rLdPDI, and rLdelF-2, were measured
in PBMCs of treated Leishmania patients as well as healthy
contacts. The levels of IFN-γ, TNF-α, and IL-12 (Th1 cytokines)
were found to be upregulated as compared to Th2 cytokines (IL-4,
IL-10, and TGF-β) as shown in Table 3.
DISCUSSION
Successful recovery from VL due to L. donovani is associated
with the development of lifelong immunity and resistance to
reinfection. In view of this fact, that generation of a strong
CMI response play a pivotal role in controlling VL, T-cell
stimulatory antigens were thought to be good vaccine targets
(Kamhawi et al., 2014). Exploration of such antigens from
Indian L. donovani parasite resulted in the identification of
F2 fraction (ranging from 89.9 to 97.1 kDa) that elicited
cellular responses in PBMCs/lymphocytes of treated Leishmania
patients/hamsters (Kumari et al., 2008a). Further, proteomic
analysis of F2 fraction revealed 18 proteins (Kumari et al., 2008b)
and out of these, 15 viz. elF-2, p45, Aldo, Eno, TPI, PDI, iPGM,
ADHT, Cal, Hsp70, Hsp83, TPR, NAD, Hypo 1 and 2 were
developed as recombinant ones. Most of these recombinant
proteins were individually characterized biochemically and
immunologically as potential vaccine candidates (Kushawaha
et al., 2011, 2012a,b; Gupta et al., 2012, 2014; Jaiswal et al.,
2014; Khare et al., 2014; Baharia et al., 2015). However, to select
the most potential one(s) for further advancement toward the
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FIGURE 1 | Lymphoproliferative response and NO production. (A) LTT response in lymph node cells of treated Leishmania-infected hamsters in response to 15
recombinant proteins and SLD (10 µg/ml each) and (B) Nitric oxide production measured by Griess reagent in supernatants collected from J774 A.1 macrophage
cultures 24 h after incubation. Each bar represents the pooled data (mean ± SE). Significance values indicate the difference in stimulation between the SLD and the
recombinant proteins (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001).
development of an effective poly-protein vaccine against VL, all
these recombinant Th1 stimulatory proteins were simultaneously
evaluated for their immunogenicity in PBMCs/lymphocytes of
treated Leishmania patients/hamsters. The observation made
herein indicated toward the potentiality of seven recombinant
proteins viz. Eno, Aldo, p45, TPI, PDI, elF-2, and Hsp70
which was well-supported by the findings in other parasitic
and infectious diseases highlighting them as a suitable vaccine
candidates (Palm et al., 2003; Pal-Bhowmick et al., 2007; Avilan
et al., 2011; Li et al., 2011; Chen et al., 2012; Matsubayashi et al.,
2013; McNulty et al., 2013; Wang et al., 2013; Zinsser et al., 2013).
As stated earlier that due to the genetic polymorphism of
the mammalian immune system, a multicomponent vaccine
is considered to evoke a better protective immune response.
Therefore, as a result, Q protein, Leish-111f, Leish-110f, KSAC,
etc., came into existence that have been demonstrated to afford
better protection against experimental VL (Molano et al., 2003;
Parody et al., 2004; Coler et al., 2007; Trigo et al., 2010; Goto
et al., 2011). Among these polyprotein vaccines, Leish-110f is
under clinical trial in Indian population and the outcome of
this vaccination trial is yet to be seen. However, since, the
strains of L. donovani in East Africa and L. infantum in the
Mediterranean Basin are markedly heterogeneous and genetically
different from Indian strains (Abass et al., 2015) it is imperative
to design and develop an indigenous polyprotein/polytope
vaccine.
Since, L. donovani infection in Syrian golden hamster
closely mimics systemic infection in human, producing similar
clinicopathological symptoms, the animal represents as an ideal
model for progressive VL (Garg and Dube, 2006). Therefore,
the cellular immune response of these recombinant proteins was
studied in lymphocytes of treated Leishmania-infected hamsters
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FIGURE 2 | Lymphoproliferative response in PBMCs of treated VL patients in response to 15 recombinant proteins and SLD (10 µg/ml each). Each bar
represents the pooled data (mean ± SE). Significance values indicate the difference in stimulation between the SLD and the recombinant proteins (∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001).
TABLE 3 | Cytokine levels in recombinant proteins and SLD stimulated PBMCs from treated VL patients (T) and healthy contacts (HC).
S. No. Treatment groups Th1 cytokines Th2 cytokines
IL-12 IFN-γ TNF-α IL-4 IL-10 TGF-β
1 SLD (T) 530.8 (75.88);
(320.1–741.5)
127.2 (16.23);
(88.82–165.6)
603.6 (63.66);
(453.1–754.2)
206.5 (61.25);
(61.64–351.3)
287.1 (66.57);
(129.7–444.6)
2567 (460.7);
(1478–3656)
2 SLD (HC) 170.9 (72.35);
(−29.98–371.8)
105.0 (21.77);
(44.54–165.4)
157.4 (67.49);
(−30.01–344.8)
225.1 (9.752);
(198.0–252.2)
44.95 (17.11);
(−2.55–92.44)
2191 (291.4);
(1382–3000)
3 p45 (T) 833.5 (139.5);
(503.5–1163)
281.7 (70.30);
(115.5–447.9)
360.3 (104.3);
(113.7–606.8)
204.7 (55.81);
(72.67–336.6)
322 (32.76);
(244.5–399.4)
2758 (387);
(1843–3673)
4 p45 (HC) 214.4 (117.9);
(−112.9–541.6)
502.0 (162.0);
(52.35–951.7)
204.4 (65.67);
(22.04–386.7)
234.3 (18.25);
(183.7–285.0)
23.33 (6.862);
(4.275–42.38)
2314 (376.7);
(1268–3360)
5 Eno (T) 668.6 (162.4);
(284.7–1053)
226.4 (36.63);
(139.8–313.0)
734.2 (206.5);
(245.9–1222)
161.8 (37.02);
(74.26–249.3)
304.3 (42.8);
(203.1–405.5)
2712 (403.8);
(1757–3666)
6 Eno (HC) 492.1 (156.3);
(58.18–926.1)
435.9 (161.2);
(−11.65–883.4)
193.4 (43.43);
(72.84–314.0)
197.8 (24.88);
(128.7–266.9)
42.49 (9.393);
(16.41–68.57)
2773 (263.6);
(2042–3505)
7 Aldo (T) 1389 (131.2);
(1079–1699)
284.6 (88.65);
(74.97–494.2)
769.0 (224.2);
(238.9–1299)
208.0 (43.50);
(105.1–310.8)
294.1 (33.08);
(215.9–372.3)
3278 (170.9);
(2873–3682)
8 Aldo (HC) 165.4 (24.46);
(97.46–233.3)
328.0 (106.2);
(33.24–622.7)
405.5 (99.87);
(128.2–682.7)
271.5 (21.41);
(212.0–330.9)
39.13 (7.734);
(17.66–60.6)
2698 (590);
(1060–4336)
9 TPI (T) 621.4 (119.2);
(339.6–903.2)
301.7 (60.08);
(159.6–443.7)
724.9 (164.9);
(334.9–1115)
190.9 (57.15);
(55.71–326.0)
253.6 (26.93);
(189.9–317.3)
2547 (457.4);
(1465–3629)
10 TPI (HC) 210.9 (84.67);
(−24.15–446.0)
241.1 (52.63);
(95.0–387.3)
289.1 (63.22);
(113.5–464.6)
239.8 (11.78);
(207.0–272.5)
26.15 (4.724);
(13.03–39.26)
2733 (786.2);
(550.5–4916)
11 PDI (T) 644.9 (46.05);
(536.0–753.8)
386.9 (100.3);
(149.7–624.1)
886.5 (249.3);
(297–1476)
191.0 (54.32);
(62.55–319.5)
265.7 (42.08);
(166.2–365.1)
2679 (415.8);
(1695–3662)
12 PDI (HC) 185.4 (76.55);
(−27.16–397.9)
340.6 (93.41);
(81.21–599.9)
200.3 (55.16);
(47.10–353.4)
222.0 (17.58);
(173.2–270.8)
50.4 (12.18);
(16.59–84.21)
1705 (160);
(1260–2149)
13 elF-2 (T) 571.0 (116.3);
(296.0–846.0)
310.4 (82.51);
(115.3–505.5)
837.6 (204.3);
(354.5–1321)
228.5 (67.02);
(69.97–386.9)
272.7 (34.27);
(191.7–353.8)
2515 (490.7);
(1355–3675)
14 elF-2 (HC) 204.8 (98.27);
(−68.03–477.7)
370.3 (160.4);
(−75.09–815.6)
321.4 (90.38);
(70.43–572.3)
222.9 (9.96);
(195.2–250.5)
32.91 (8.252);
(9.998–55.82)
3818 (1125);
(695.6–6940)
Values are displayed as mean (SE); (95% confidence interval).
and was further validated in PBMCs of treated VL patients and
healthy contacts.
A range of factors may contribute to the immunogenicity of
proteins in VL patients but a major driver for immunogenicity
is likely to be the T-cells. Therefore, T-cell function is analyzed
by LTT as it can indicate toward T-cell activation. In this study
10 out of 15 proteins viz. Eno, Aldo, p45, TPI, PDI, elF-2,
Hsp83, ADHT, and Hypo 1 and 2 showed a better proliferative
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response in lymphocytes of treated hamster. Further, since NO is
up-regulated by IFN-γ, in the absence of commercially available
cytokine reagents for hamsters, the same was estimated indirectly
using NO assay. Herein, six out of above stated 10 proteins
with the better lymphoproliferative response, i.e., Eno, Aldo, p45,
TPI, PDI, and elF-2 have shown optimally good NO response
indicating toward their being highly immunogenic.
However, among all the 15 recombinant proteins, only
seven proteins viz. Eno, Aldo, p45, TPI, PDI, elF-2, and
Hsp70 exhibited good T-cell reactivity in PBMCs of treated VL
patients and healthy contacts endorsing the observations made in
lymphocytes of treated hamster. These six proteins, when further
evaluated for their cytokine response in PBMCs, generated
Th1 type immune response which was characterized by high
production of IFN-γ, IL-12 and TNF-α against the recombinant
proteins as compared to SLD and a low production of IL-4 and
IL-10 which was inferior to SLD. The LTT response, as well as
the cytokine levels in both the study groups, was comparable,
suggesting that the exposed population to Leishmania infection,
develop a strong protective immunity as was also observed by
Tripathi et al. (2006).
CONCLUSION
This study shows that PBMCs and lymphocytes from treated
VL patients and hamsters were able to recognize six potential
Th1 stimulatory recombinant Leishmania proteins with the
production of Th1 type cytokines that are associated with
Leishmania killing. These findings lead to the first step of selecting
superior vaccine targets. Now these proteins can be further
subjected to the identification of potential antigenic peptides
(epitope) using various immunoinformatic tools that can be
better utilized for designing poly-epitope vaccine in order to
fortify host immunity against dreaded kala-azar disease. This new
vaccine approach to treat VL expands host protective immune
responses, making host produce beneficial T-cells that alleviate
disease symptoms more quickly.
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